Outset Medical, Inc. (NASDAQ:OM) Given Consensus Recommendation of “Hold” by Analysts

Shares of Outset Medical, Inc. (NASDAQ:OM) have received a consensus rating of “Hold” from the five research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $10.00.

A number of equities research analysts have recently issued reports on OM shares. Wall Street Zen upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings cut shares of Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st.

Institutional Investors Weigh In On Outset Medical

A number of institutional investors have recently bought and sold shares of the business. BML Capital Management LLC boosted its holdings in shares of Outset Medical by 250.2% during the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock worth $7,304,000 after purchasing an additional 1,359,021 shares during the period. Renaissance Technologies LLC increased its stake in Outset Medical by 391.3% in the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after buying an additional 176,870 shares during the period. Sei Investments Co. lifted its position in Outset Medical by 15.5% in the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock worth $136,000 after buying an additional 4,738 shares in the last quarter. R Squared Ltd purchased a new stake in Outset Medical in the 1st quarter worth approximately $65,000. Finally, Aristides Capital LLC acquired a new stake in shares of Outset Medical during the 4th quarter valued at $177,000.

Outset Medical Stock Performance

Shares of NASDAQ OM opened at $3.59 on Monday. The business has a fifty day simple moving average of $4.42 and a 200-day simple moving average of $4.19. The company has a market cap of $67.49 million, a price-to-earnings ratio of -0.88 and a beta of 1.90. Outset Medical has a 12 month low of $3.00 and a 12 month high of $16.16. The company has a quick ratio of 4.11, a current ratio of 5.19 and a debt-to-equity ratio of 1.03.

Outset Medical (NASDAQ:OM) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The firm had revenue of $31.64 million for the quarter, compared to analysts’ expectations of $28.97 million. Sell-side analysts predict that Outset Medical will post -3.81 EPS for the current year.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.